# Comparing Heavy Levobupivacaine With Enantiomeric Excess of 50% and Heavy Racemic Bupivacaine.

> **NCT01308047** · PHASE3 · WITHDRAWN · sponsor: **Cristália Produtos Químicos Farmacêuticos Ltda.**

## Conditions studied

- Fracture of Lower Limb

## Interventions

- **DRUG:** Bupivacaine

## Key facts

- **NCT ID:** NCT01308047
- **Lead sponsor:** Cristália Produtos Químicos Farmacêuticos Ltda.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The Sponsor has no interest in continuing the study.
- **Last updated:** 2014-03-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01308047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01308047, "Comparing Heavy Levobupivacaine With Enantiomeric Excess of 50% and Heavy Racemic Bupivacaine.". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT01308047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*